Givosiran, developed by Alnylam, targets 5′-aminolevulinate synthase 1 (ALAS1) for the treatment of acute hepatic porphyria and received FDA approval in November 2019 [29]. The gene discussed is ALAS1; the disease is Acute hepatic porphyria.